All In Biotech

Drug Trial Radar · NCT06492070

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Trial of Cryocompression With or Without Cilostazol

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cryocompression is a therapy that combines compression garments or dressings with cooling of the treated area. Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs. Giving cilostazol together with cryocompression may be safe and tolerable in treating patients with gynecological cancers.

Conditions

  • Cervical Carcinoma
  • Fallopian Tube Carcinoma
  • Malignant Solid Neoplasm
  • Malignant Uterine Neoplasm
  • Ovarian Carcinoma
  • Primary Peritoneal Carcinoma
  • Vulvar Carcinoma

Interventions

  • Best PracticeOther

    Undergo standard of care

  • CilostazolDrug

    Given PO

  • Cryocompression TherapyDevice

    Undergo cryocompression therapy

  • PaclitaxelDrug

    Given by infusion

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in sensation and vibration objective neuropathy scores (Arms A and B)Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months
  2. Rates of impaired sensation and vibration on objective neuropathy testing and ≥ Grade 2 neuropathy among patients who recently completed paclitaxel treatment with standard of care treatment protocols (Arm C)Time frame: At 1 month post chemotherapy completion and at 6 months and 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Not yet recruiting

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.